Overall survival and clinical characteristics of BRCA mutation carriers with stage I/II pancreatic cancer.

PubWeight™: 0.75^‹?›

🔗 View Article (PMID 28183138)

Published in Br J Cancer on February 09, 2017

Authors

Talia Golan¹^,2, Tal Sella¹^,2, Eileen M O'Reilly³^,4, Matthew H G Katz⁵, Ron Epelbaum⁶^,7, David P Kelsen³^,4, Ayelet Borgida⁸, Hannah Maynard³^,4, Hedy Kindler⁹, Eitan Friedmen²^,10, Milind Javle¹¹, Steven Gallinger⁸

Author Affiliations

1: Department of Oncology, Sheba Medical Center, Ramat Gan 52621, Israel.
2: Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.
3: Department of Medicine, Memorial Sloan Kettering Cancer Center New York, New York, NY 10065, USA.
4: Weill Cornell Medical College New York, New York, NY 10065, USA.
5: Department of Surgical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.
6: Department of Oncology, Rambam Health Care Campus, Haifa 3109601, Israel.
7: The Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa 3109601, Israel.
8: Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, ON M5G 1X5, Canada.
9: Section of Hematology/Oncology, University of Chicago, Chicago, IL 60637, USA.
10: The Susanne Levy Gertner Oncogenetics Unit, Sheba Medical Center, Ramat Gan 52621, Israel.
11: Department of Gastrointestinal Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.

Articles cited by this ↗

The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol (2010) 24.32

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med (2011) 24.32

Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol (2014) 5.97

Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet (1996) 4.36

Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA (2013) 3.46

The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%. Nat Genet (1996) 2.82

The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. Am J Hum Genet (1997) 2.28

Improvement of surgical results for pancreatic cancer. Lancet Oncol (2013) 1.60

An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions. Oncologist (2011) 1.44

BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma. J Clin Oncol (2008) 1.36

Vascular resection in pancreatic cancer surgery: survival determinants. J Gastrointest Surg (2009) 1.33

Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer. Anticancer Res (2011) 1.14

Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers. Br J Cancer (2014) 1.08

Cancer mortality in relatives of women with ovarian cancer: the OPCS Study. Office of Population Censuses and Surveys. Int J Cancer (1996) 1.05

Modest improvement in overall survival for patients with metastatic pancreatic cancer: a trend analysis using the surveillance, epidemiology, and end results registry from 1988 to 2008. Pancreas (2013) 1.00

Subtyping Pancreatic Cancer. Cancer Cell (2015) 0.81